-

09:45:33 PM

RVVTF Stock News

RVVTF - Revive Therapeutics Ltd.

06/24/22 11:41 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company

RHEA-AI

neutral

06/06/22 1:54 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences

RHEA-AI

neutral

05/31/22 7:00 AM

OTC : RVVTF

Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis Company intends to

RHEA-AI

neutral

05/26/22 10:15 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life

RHEA-AI

neutral

05/16/22 10:48 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

RHEA-AI

neutral

04/25/22 4:42 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an

RHEA-AI

neutral

04/18/22 9:43 AM

OTC : RVVTF

covid-19

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the

RHEA-AI

neutral

04/11/22 5:54 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an

RHEA-AI

neutral

03/29/22 8:45 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”)

RHEA-AI

neutral

02/15/22 4:26 PM

OTC : RVVTF

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that

RHEA-AI

neutral

RVVTF Data

IndustryPharmaceuticals: Major
Websitehttp://www.revivethera.com
CeoMichael Frank
Security nameRevive Therapeutics Ltd.
Issue typecs
SectorHealth Technology
Sic code2834
Tags
- Pharmaceuticals: Major
- Health Technology
AddressThe Canadian Venture Building
StateON
CityToronto
ZipM5C
CountryCA
Phone1.888.901.0036

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. engages in the research, development, and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets. It offers the Relicann, a proprietary hemp-based cannabidiol chewing gum for the health and wellness. Its novel cannabinoid delivery technology targets diseases and disorders such as pain, inflammation, and wound care. The company was founded by Fabio Chianelli on March 27, 2012 and is headquartered in Toronto, Canada.